Novartis AG

NVSNYSEPharmaceutical PreparationsFiscal year ends December 31Also trades as NVSEF

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 20-F on Feb 4, 2026Score 7/30

$161.52+0.73 (+0.45%)

Close on Nov 2, 2026Market cap $308.21BP/E 22.6Yield –

Novartis 1. Marketing & Sales FTEs by Year

Name: Novartis 1. Marketing & Sales FTEs by Year (NVS)
Creator: Novartis

Novartis 1. Marketing & Sales FTEs: 27,288 in FY2025, down 5.2% from a year earlier.

Latest, FY2025

27,288

Period ended Dec 31, 2025

Change on a year earlier

-5.2%

28,786 in FY2024

History

3 years

Since FY2023

Sources

Novartis Form 20-F (0001114448-26-000004)

Where the FY2025 figure comes from

“|| Total | 27 288 | 20 015 | 16 487 | 11 477 | 75 267”

Source: Novartis Form 20-F (0001114448-26-000004) ↗

Reported in Form 20-F Item 6.D.

Annual history

Hover a value to see the sentence it was read from; calculated values show their formula

Period	Ended	1. Marketing & Sales FTEs	Year on year	Source
FY2025	Dec 31, 2025	27,288	-5.2%	Novartis Form 20-F (0001114448-26-000004) ↗
FY2024	Dec 31, 2024	28,786	-2.0%	Novartis Form 20-F (0001114448-26-000004) ↗
FY2023	Dec 31, 2023	29,388	–	Novartis Form 20-F (0001114448-26-000004) ↗

Breakdown

What makes up 1. Marketing & Sales FTEs

Cite this data

StockData. (2026). Novartis 1. Marketing & Sales FTEs, annual FY2023–FY2025 [Data set]. Compiled from Novartis SEC filings and investor materials. https://stockdatahq.com/stocks/nvs/kpis/wf-fte-mktg-sales

See every metric in the Novartis KPI table. Data updated Nov 2, 2026.